Seres Therapeutics Price Target Maintained With a $1.25/Share by Chardan Capital

Dow JonesMar 20 16:31 ET

Seres Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesMar 20 16:31 ET

Piper Sandler Downgrades Seres Therapeutics(MCRB.US) to Hold Rating, Cuts Target Price to $1

Moomoo NewsMar 15 02:31 ET

Seres Therapeutics Analyst Ratings

BenzingaMar 14 13:59 ET

Seres Therapeutics (MCRB) Gets a Hold From Piper Sandler

TipRanksMar 14 06:37 ET

TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating

Moomoo NewsMar 14 02:31 ET

Seres Therapeutics: Strategic Developments and Promising Clinical Data Justify Buy Rating

TipRanksMar 13 13:02 ET

TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating

Moomoo NewsJan 10 07:31 ET

Seres Therapeutics (MCRB) Receives a Buy From TD Cowen

TipRanksJan 10 07:21 ET

Optimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost Confidence

TipRanksDec 10, 2024 06:47 ET

Seres Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow JonesNov 14, 2024 11:21 ET

Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity

Dow JonesNov 14, 2024 11:21 ET

Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics

TipRanksNov 14, 2024 07:30 ET

Seres Therapeutics Analyst Ratings

BenzingaNov 13, 2024 18:57 ET

Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

BenzingaNov 13, 2024 18:57 ET

TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating

Moomoo NewsNov 13, 2024 11:32 ET

Seres Therapeutics (MCRB) Gets a Buy From TD Cowen

TipRanksNov 13, 2024 10:58 ET

Seres Therapeutics Analyst Ratings

BenzingaOct 24, 2024 07:09 ET

J.P. Morgan Downgrades Seres Therapeutics(MCRB.US) to Sell Rating

Moomoo NewsOct 23, 2024 18:31 ET

Seres Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow JonesSep 13, 2024 14:48 ET